In this online CME self-learning program:
Alcohol use disorder (AUD), referred to colloquially as alcoholism, is an integration of past terms that have include in past as alcohol dependence or abuse, and may be marked by any one of a number of different symptoms or behaviors that include physical cravings, compulsion, guilt, and frequent consumption over an extended period of time. There are about 7.9 million people in the United States who suffer from the disease, but a fraction – 2.2 million people – seek treatment for it. The number of people who are considered heavy drinkers is about double at somewhere between 15.9 and 17.6 million, and just under a quarter of Americans over age 12 reports having engaged in binge drinking at least once in the last month. Alcohol accounts for over 687,000 emergency department visits by people under age 20 per year, and AUD is estimated to cost $223.5 billion per year. Worldwide, 76.3 million people are estimated to have AUDs, and they account for an annual mortality rate of 1.8 million. AUD is largely undertreated, constituting one gap in care and justifying CME.
Primer on AUD’s epidemiology, what is known in the neuropathophysiology, screening strategies, and psychosocial impact [Learning Objective #1]
Treatment of AUD [Learning Objective #3 & 4]
Summary, conclusions, and best practice recap
Healthcare professionals who are: psychiatrists, primary care physicians, emergency medicine physicians, physician assistants, nurse practitioners, pharmacists, and those who otherwise commonly treat patients suffering from or have a clinical interest in AUD.
This program is supported by an educational grant from Alkermes.
Release Date: October 13, 2017 -- Expiration Date: October 13, 2019
Faculty: Timothy Fong, MD
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Timothy Fong, M.D., Professor of Psychiatry Director, UCLA Addiction Psychiatry Fellowship UCLA School of Medicine, Los Angeles, CA is on the Speaker’s Bureau of Indivior, has received Research Support from Connections in Recovery and Constellation Health and is a consultant for Onward, Inc. and Alkermes
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Alkermes
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Best Practices and Advances in Treatment Strategies in Bipolar Disorder Pharmacotherapy
Schizophrenia: Updates from the American Psychiatric Association Annual Meeting (APA) 2017
Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices
Major Depressive Disorder (MDD): Updates from the American Psychiatric Association Annual Meeting (APA) 2017